Company Overview and News

126
Sarepta Pharma Pushes Two Biotech ETFs to New Highs

2018-06-20 zacks
Sarepta Therapeutics Inc. (SRPT - Free Report) was a star performer in Tuesday’s trading session, as the stock skyrocketed as much as 57.7% to a new high of $176.50 but closed a little lower, rising 36.8% (read: 4 Sector ETFs That Crushed S&P 500 in 9-Year Bull Run). The surge propelled the company’s market cap from $6.9 billion to more than $9 billion, making it the fifth most valuable drugmaker headquartered in Massachusetts, behind Biogen (BIIB - Free Report) , Vertex Pharmaceuticals (VRTX - Free Report) , Alexion Pharmaceuticals (ALXN - Free Report) and Alnylam Pharmaceuticals (ALNY - Free Report) .
SBIO VRTX ALXN BIIB SLDB SRPT IBB ALNY

0
CF Drugmaker Vertex More Than Doubles R&D Space in San Diego

2018-06-19 biospace
Vertex Pharmaceuticals has substantially expanded the San Diego-based research and development facility that discovered its three breakthrough cystic fibrosis (CF) medicines. The new space includes 170,000 square feet of research space.
VRTX

11
CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing

2018-06-19 globenewswire
ZUG, Switzerland and CAMBRIDGE, Mass. and BERKELEY, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA), and Caribou Biosciences, Inc., announced that The Regents of the University of California, the University of Vienna and Emmanuelle Charpentier, Ph.D. (collectively, “UC”), co-owners of foundational intellectual property relating to CRISPR/Cas9 genome editing technology, were granted U.
NTLA VRTX CRSP

164
Biotech Leadership Transformations: Week of June 11th

2018-06-18 biospace
Biotech companies continue to make moves to strengthen senior leadership teams and drive growth. Below is a roundup of some noted movers and shakers for the week of June 11 - 15.
ABT ENTA VRTX CELGZ RCUS BIOAF AIMT EBIO ABT BOLD SESN NVLN ARNA CELG BTI

208
Brief Mid-Year Update On 2018 Global Asset Allocation

2018-06-15 seekingalpha
This brief update is meant to be read along with a review of my extensive December 28, 2017 note for many more details.
VRTX REGN AMGN GILD BIIB RGORF CELG AEM GOLD RRS GOLD

211
10 Stocks That Are Screaming Buys Right Now

2018-06-12 investorplace
Buckle up — the market is looking jittery right now. If it’s not the threat of further Federal interest rate hikes, it’s the possibility of a full-blown trade war with China and Europe. As James Brumley notes, however, if geopolitical risks were actually a deterrent to investing “nobody would ever put (or keep) a penny in stocks”.
MTZ FB VRTX BABA TWOU ALXN BOE PXD RTN SKX BA

37
Crispr Therapeutics: Beware Of Articles Minimizing The Clinical Hold Risk

2018-06-11 seekingalpha
Articles published last week appear to be examples of confirmation bias showing too little regard for the potential risk factors associated with CRISRP editing.
NTLA VRTX EDIT BLUE CRSP BLUE

51
Crispr Therapeutics: What The FDA Clinical Hold On CTX-001 For Sickle Cell Disease Entails

2018-06-08 seekingalpha
FDA placed a clinical hold on CTX-001 for the sickle cell disease development. Innovation for CTX-001 in Europe will continue as planned. The phase 1/2 trial for beta-thalassemia is expected.
VRTX GERN SLDB CRSP

17
Proteostasis Falls On Phase 1 Data, But Was Greatly Misunderstood

2018-06-08 seekingalpha
Proteostasis Therapeutics tumbles on release of phase 1 data, but I believe that the results were misunderstood.
VRTX PTI

37
After Soaring to New Highs, Crispr Therapeutics AG Stock Ripe for a Fall

2018-06-05 investorplace
Quite often in stock markets, companies that offer something novel and unique attract speculators. So, when Crispr Therapeutics AG (NASDAQ:CRSP) quadrupled from 52-week lows, investors naturally questioned its valuation against its prospects.
VRTX GILD SGMO CRSP

10
CRISPR Therapeutics to Participate in Three June Conferences

2018-06-05 globenewswire
ZUG, Switzerland and CAMBRIDGE, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to present at three conferences in June 2018.
VRTX CRSP

10
BIO 2018 is the International Convention’s 25th Year

2018-06-04 biospace
The BIO International Convention will be officially running from June 4 through June 7, although activities began on Friday, June 1. Hosted by the Biotechnology Innovation Organization (BIO), the convention represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organization across the U.S. and the world.
VRTX BIO.B ARCT BIO KAOCF

87
Palatin shares up 9% premarket

2018-06-04 marketwatch
Palatin Technologies Inc. shares surged 9% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has accepted the new drug application for bremelanotide, a treatment for female sexual desire disorder. The NDA was filed by Amag Pharmaceuticals Inc. , Palatin's exclusive North America licensee, in March. The goal date for completion of the review is March 23, 2019. If approved, bremelanotide would be the first and only treatment for hypoactive sexual desire disorder (HSDD) in pre-menopausal women.
VRTX AMAG DISCB DISCA PTN NYTAB DISCK FOSL DISC

10
Crispr Stock Tumbles On FDA Clinical Hold, But European Study Remains On Track

2018-06-04 seekingalpha
Crispr Therapeutics received a clinical hold from the FDA for an IND on CTX-001 in treating patients with sickle cell disease.
SCD VRTX CRSP IND

330
Key FDA Events in June Investors Need to Watch Out For

2018-06-01 zacks
It has been a busy year for the FDA so far with the agency approving 14 drugs. Key approvals include Novartis’ Lutathera, Gilead Sciences’ HIV regimen, Biktarvy; Vertex Pharmaceuticals’ Symdeko (tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF), Johnson & Johnson’s Erleada for prostate cancer, Amgen’s Aimoviq for the treatment of migraine, BioMarin’s Palynziq for the treatment of phenylketonuria, and Dova Pharmaceuticals Doptelet among others.
VRX VRTX ALKS GILD AKAO ARRY GWP

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

7h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

8h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to VRTX / Vertex Pharmaceuticals Inc. on message board site Silicon Investor.

Vertex Pharmaceuticals (VRTX) VRTX: Vertex Pharmaceuticals
CUSIP: 92532F100